ReviewMovement disorders : official journal of the Movement Disorder Society2014
What can biomarkers tell us about cognition in Parkinson's disease?
Review in Movement disorders : official journal of the Movement Disorder Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Predictors of cognitive impairment in Parkinson's disease: a systematic review and meta-analysis of prospective cohort studies.Journal of neurology · 2021Pooled it
- Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review.Neuropsychology review · 2015Pooled it
- Corneal epithelial thickness can reflect the stage of Parkinson's disease and the severity of dry eye.Frontiers in aging neuroscience · 2026Article
- Predicting cognition after subthalamic Deep Brain Stimulation in Parkinson's Disease.NPJ Parkinson's disease · 2025Article
- Dual-task-related gait patterns as possible marker of precocious and subclinical cognitive alterations in Parkinson disease.Scientific reports · 2025Article
- Stage-specific functional networks associated with cognitive impairment in Parkinson's disease: a pilot fNIRS study.Frontiers in aging neuroscience · 2025Article
- Article
- Review
- Article
- Interplay between gait and neuropsychiatric symptoms in Parkinson's Disease.European journal of translational myology · 2022Article
- Cognition, motor symptoms, and glycolipid metabolism in Parkinson's disease with depressive symptoms.Journal of neural transmission (Vienna, Austria : 1996) · 2022Article
- Mild Cognitive Impairment Subtypes Are Associated With Peculiar Gait Patterns in Parkinson's Disease.Frontiers in aging neuroscience · 2022Article
- Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals withFrontiers in aging neuroscience · 2022Article
- Machine learning can predict mild cognitive impairment in Parkinson's disease.Frontiers in neurology · 2022Article
- Whole Clinic Research Enrollment in Parkinson's Disease: The Molecular Integration in Neurological Diagnosis (MIND) Study.Journal of Parkinson's disease · 2021Article
- EEG Slowing and Axial Motor Impairment Are Independent Predictors of Cognitive Worsening in a Three-Year Cohort of Patients With Parkinson's Disease.Frontiers in aging neuroscience · 2020Article
- Visual self-motion cues are impaired yet overweighted during visual-vestibular integration in Parkinson's disease.Brain communications · 2020Article
- Advance care planning in Parkinson's disease: ethical challenges and future directions.NPJ Parkinson's disease · 2019Review
- Step length predicts executive dysfunction in Parkinson's disease: a 3-year prospective study.Journal of neurology · 2018Article
- Finding useful biomarkers for Parkinson's disease.Science translational medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 4 countries.
Funding
Abstract
Cognitive decline is common in Parkinson's disease (PD), even in the early motor stage, and this non-motor feature impacts quality of life and prognosis tremendously. In this article, we discuss marker candidates for cognitive decline in PD from different angles, including functional and structural imaging techniques, biological fluid markers in cerebrospinal fluid, and blood genetic predictors, as well as gait as a surrogate marker of cognitive decline. Specifically, imaging-based markers of cognitive impairment in PD include cortical atrophy, reduced cortical metabolism, loss of cortical cholinergic and frontal dopaminergic function, as well as an increased cortical amyloid load. Reduced β-amyloid(1-42) in cerebrospinal fluid and lower plasma levels of epidermal growth factor are predictors for cognitive decline in PD. In addition, genetic variation in the apolipoprotein E (APOE), catechol-O-methyltransferase (COMT), microtubule-associated protein tau (MAPT), and glucocerebrosidase (GBA) genes may confer risk for cognitive impairment in PD; and gait disturbance may also indicate an increased risk for dementia. Other marker candidates have been proposed and are discussed. All of the current studies are hampered by gaps in our knowledge about the molecular causes of cognitive decline, which will have to be considered in future biomarker studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.